Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
11h
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for ...
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...
Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback